The company's Targeted Antibody Payload (TAP) technology uses antibodies to deliver a potent cytotoxic agent to treat various cancers, including metastatic breast cancer, hematological malignancies, non-Hodgkin's lymphoma, and solid tumors. ImmunoGen's products are in various stages of clinical trials, and the company has licensing or collaboration agreements with several pharmaceutical companies. ImmunoGen aims to develop the most precise, targeted cancer therapies to get people back to their lives.